PathToScale: The PERSIST Trial
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age15-110
SponsorGeorgetown University
About this trial
The purpose of this study is to identify the effectiveness of a bundle of strategies to support continuation of clients on pre-exposure prophylaxis, including long-acting injectable cabotegravir and oral pre-exposure prophylaxis to high priority groups.
Eligibility criteria
Qualifiers
Female sex workers (FSW) OR
Men who have sex with men (MSM) OR
Transgender individuals (TG) OR
Women and adolescent girls and young women (AGYW) presenting at STI services and/or family planning and/or HIV testing services OR
Disqualifiers
None
Trial design
Treatments tested in this trial
- Standard of Care (SoC)
- Enhanced continuation support package
Treatment groups
9,900 Participants
are divided into 2 treatment groupsSponsors and collaborators
Georgetown University
Lead sponsor
Center for the Development of People
Collaborator
Centers for Disease Control and Prevention
Collaborator
Elizabeth Glaser Pediatric AIDS Foundation
Collaborator
Healthqual
Collaborator
Johns Hopkins Research Project, Malawi
Collaborator
Johns Hopkins Bloomberg School of Public Health
Collaborator
Blantyre District Health Office, Malawi
Collaborator
Lilongwe District Health Office, Malawi
Collaborator
Lighthouse Trust
Collaborator
Ministry of Health, Malawi
Collaborator
National AIDS Commission, Malawi
Collaborator
Pakachere Institute of Health and Development Communication
Collaborator
Partners in Hope, Inc.
Collaborator
University of North Carolina, Chapel Hill
Collaborator
United States President's Emergency Plan for AIDS Relief
Collaborator
Washington University School of Medicine
Collaborator
Clinton Health Access Initiative Inc.
Collaborator
Quantitative Engineering Design
Collaborator
Source ClinicalTrials.gov